PL2520575T3 - Związek 1,3,4-oksadiazolo-2-karboksyamidowy - Google Patents

Związek 1,3,4-oksadiazolo-2-karboksyamidowy

Info

Publication number
PL2520575T3
PL2520575T3 PL10841060T PL10841060T PL2520575T3 PL 2520575 T3 PL2520575 T3 PL 2520575T3 PL 10841060 T PL10841060 T PL 10841060T PL 10841060 T PL10841060 T PL 10841060T PL 2520575 T3 PL2520575 T3 PL 2520575T3
Authority
PL
Poland
Prior art keywords
oxadiazole
carboxamide compound
carboxamide
compound
Prior art date
Application number
PL10841060T
Other languages
English (en)
Inventor
Akira Asai
Kenji Matsuno
Naohisa Ogo
Osamu Takahashi
Yoshiaki Masuda
Ayumu Muroya
Yasuto Akiyama
Tadashi Ashizawa
Tadashi Okawara
Original Assignee
General Incorporated Association Pharma Valley Project Supporting Organization
Shizuoka Prefecture
Kumamoto Health Science University
Kabushiki Kaisha Yakult Honsha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Incorporated Association Pharma Valley Project Supporting Organization, Shizuoka Prefecture, Kumamoto Health Science University, Kabushiki Kaisha Yakult Honsha filed Critical General Incorporated Association Pharma Valley Project Supporting Organization
Publication of PL2520575T3 publication Critical patent/PL2520575T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL10841060T 2009-12-28 2010-12-28 Związek 1,3,4-oksadiazolo-2-karboksyamidowy PL2520575T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009297960 2009-12-28
EP10841060.6A EP2520575B1 (en) 2009-12-28 2010-12-28 1,3,4-oxadiazole-2-carboxamide compound

Publications (1)

Publication Number Publication Date
PL2520575T3 true PL2520575T3 (pl) 2017-05-31

Family

ID=44226607

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10841060T PL2520575T3 (pl) 2009-12-28 2010-12-28 Związek 1,3,4-oksadiazolo-2-karboksyamidowy

Country Status (13)

Country Link
US (1) US8796320B2 (pl)
EP (1) EP2520575B1 (pl)
JP (1) JP5794922B2 (pl)
KR (1) KR101778320B1 (pl)
CN (1) CN102725287B (pl)
AU (1) AU2010339271B2 (pl)
CA (1) CA2785679C (pl)
EA (1) EA022458B1 (pl)
ES (1) ES2610248T3 (pl)
NZ (1) NZ600837A (pl)
PL (1) PL2520575T3 (pl)
TW (1) TWI523851B (pl)
WO (1) WO2011081205A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388468B (es) 2009-12-04 2025-03-20 Sunovion Pharmaceuticals Inc Compuestos multicíclicos y métodos de uso de los mismos.
EA031618B1 (ru) * 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
EP3373935B1 (en) * 2015-11-12 2021-09-01 Merck Sharp & Dohme Corp. Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use
MY199446A (en) 2016-07-29 2023-10-28 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
WO2018023070A1 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
KR102341660B1 (ko) 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
AU2018220509B2 (en) 2017-02-16 2022-04-28 Sumitomo Pharma America, Inc. Methods of treating schizophrenia
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
CN110494166B (zh) 2017-05-02 2022-11-08 诺华股份有限公司 组合疗法
KR20200036008A (ko) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
CN109535146B (zh) * 2017-09-21 2020-09-22 中国医学科学院医药生物技术研究所 抗结核化合物及其制备方法和用途
MY208150A (en) 2018-02-16 2025-04-18 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
US11447482B1 (en) 2019-02-14 2022-09-20 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
MX2021012216A (es) 2019-04-05 2022-01-24 Kymera Therapeutics Inc Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
BR112021022335A2 (pt) 2019-05-13 2021-12-28 Novartis Ag Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
MX2022001019A (es) 2019-07-31 2022-02-22 Ribon Therapeutics Inc Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
WO2021049311A1 (ja) * 2019-09-09 2021-03-18 エロビクス・アーベー 1,5-ベンゾチアゼピン化合物を製造するための方法
JP7781768B2 (ja) 2020-04-14 2025-12-08 スミトモ・ファーマ・アメリカ・インコーポレイテッド 神経学的および精神障害の治療方法
WO2022216930A1 (en) * 2021-04-08 2022-10-13 Virginia Commonwealth University Novel mda-9 antagonist with anti-metastatic potential
TW202434222A (zh) * 2022-12-31 2024-09-01 大陸商南京艾美斐生物醫藥科技有限公司 作為巨噬細胞遷移抑制因子抑制劑之化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429593B2 (en) * 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
WO2004058753A1 (en) 2002-05-06 2004-07-15 Vertex Pharmaceuticals Incorporated Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase
US7683097B2 (en) * 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
EP1802606B1 (en) 2004-10-19 2011-03-16 Compass Pharmaceuticals LLC Arylcarboxamides and their use as anti-tumor agents
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
CA2736564A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
SI2299999T1 (sl) 2008-06-04 2017-12-29 Baylor Collega Of Medicine Stat3 inhibitorji
KR101696936B1 (ko) 2008-07-10 2017-01-16 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 퀴놀린카르복사미드 유도체를 유효 성분으로 하는 stat3 저해제

Also Published As

Publication number Publication date
WO2011081205A1 (ja) 2011-07-07
CA2785679C (en) 2017-12-12
NZ600837A (en) 2014-01-31
EP2520575B1 (en) 2016-11-30
US20120302524A1 (en) 2012-11-29
ES2610248T3 (es) 2017-04-26
KR101778320B1 (ko) 2017-09-13
CN102725287A (zh) 2012-10-10
AU2010339271B2 (en) 2015-09-03
TW201127832A (en) 2011-08-16
EA022458B1 (ru) 2016-01-29
US8796320B2 (en) 2014-08-05
JP5794922B2 (ja) 2015-10-14
TWI523851B (zh) 2016-03-01
EP2520575A1 (en) 2012-11-07
EP2520575A4 (en) 2013-12-11
CN102725287B (zh) 2015-07-01
AU2010339271A1 (en) 2012-07-19
CA2785679A1 (en) 2011-07-07
JPWO2011081205A1 (ja) 2013-05-13
EA201290397A1 (ru) 2013-01-30
KR20120109530A (ko) 2012-10-08

Similar Documents

Publication Publication Date Title
PL2520575T3 (pl) Związek 1,3,4-oksadiazolo-2-karboksyamidowy
EP2361902A4 (en) 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
IL215615A0 (en) Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
SI2384326T1 (sl) Pirolo(2,3-d)pirimidinske spojine
GB0913345D0 (en) New combination 802
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
GB0804989D0 (en) Compound
SI2513119T1 (sl) 3,4,4a,10b-tetrahidro-1H-tiopirano-(4,3-c)izokinolinski derivati
GB201203224D0 (en) Substitute 1,2-azaborne heterocycles
GB0900404D0 (en) New compounds 4
GB0803494D0 (en) Compound
IL214110A0 (en) 2,3-diaryl-or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
IL207035A0 (en) Benzylpiperizine compound
SI2266990T1 (sl) Spojina 3-fenilpirazolo(5,1-b)tiazola
GB0912946D0 (en) New compounds 5
AP2011005932A0 (en) Pyrazinoisoquinoline Compounds.
IL213762A0 (en) 1,1,1-trifluoro-2-hydroxypropyl compounds
ZA201202652B (en) Pesticidal compositions comprising 4,5-dihydroxyindan-1-one
GB0823316D0 (en) Compound
EP2493476A4 (en) DEUTERATED 5,6-DIHYDRO-1H-PYRIDINE-2-ON COMPOUNDS
GB0900385D0 (en) Lasha2A.1
GB0918322D0 (en) Compounds 814
GB0913344D0 (en) Compounds 762
GB0912947D0 (en) New compounds 6
GB0900400D0 (en) New compounds 3